Garen Bohlin Biography and Net Worth

Director of Karyopharm Therapeutics

Mr. Bohlin has served as a member of our Board of Directors since October 2013. Since 2012, Mr. Bohlin has focused exclusively on service on boards of directors and consulting. From 2010 until his retirement in 2012, he served as Executive Vice President of Constellation Pharmaceuticals, Inc., where he served as a part-time business partner with the Chief Executive Officer. Prior to Constellation, Mr. Bohlin served as Chief Operating Officer of Sirtris Pharmaceuticals, Inc. from 2006 to 2009, where he played key roles in the overall management of Sirtris, its initial public offering and the sale of the company to GlaxoSmithKline. Mr. Bohlin was the founding Chief Executive Officer of Syntonix Pharmaceuticals, Inc., from 1999 through 2008, where he played a key role in the overall management of Syntonix, positioning it for an eventual sale to Biogen Idec. Prior to Syntonix, Mr. Bohlin was Executive Vice President of Genetics Institute, Inc., where he played a key role in overall management, its initial public offering and its sale to American Home Products/Wyeth, and a partner at Arthur Andersen & Co. Mr. Bohlin has served on the board of directors and audit committee of Collegium Pharmaceutical, Inc. since 2015 and served on the board of directors at Tetraphase Pharmaceuticals, Inc. from 2010 until July 2020, when Tetraphase was acquired by La Jolla Pharmaceutical Company. Mr. Bohlin holds a B.S. in Accounting from the University of Illinois.

What is Garen G. Bohlin's net worth?: The estimated net worth of Garen G. Bohlin is at least $56,425.00 as of September 12th, 2023. Mr. Bohlin owns 45,140 shares of Karyopharm Therapeutics stock worth more than $56,425 as of April 19th. This net worth evaluation does not reflect any other assets that Mr. Bohlin may own. Learn More about Garen G. Bohlin's net worth.
How do I contact Garen G. Bohlin?: The corporate mailing address for Mr. Bohlin and other Karyopharm Therapeutics executives is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. Karyopharm Therapeutics can also be reached via phone at (617) 658-0600 and via email at [email protected]. Learn More on Garen G. Bohlin's contact information.
Has Garen G. Bohlin been buying or selling shares of Karyopharm Therapeutics?: Garen G. Bohlin has not been actively trading shares of Karyopharm Therapeutics within the last three months. Most recently, on Tuesday, September 12th, Garen G. Bohlin bought 41,140 shares of Karyopharm Therapeutics stock. The stock was acquired at an average cost of $1.22 per share, with a total value of $50,190.80. Following the completion of the transaction, the director now directly owns 45,140 shares of the company's stock, valued at $55,070.80. Learn More on Garen G. Bohlin's trading history.
Who are Karyopharm Therapeutics' active insiders?: Karyopharm Therapeutics' insider roster includes Garen Bohlin (Director), Michael Kauffman (Director), Michael Mason (CFO), Stephen Mitchener (SVP), Sharon Shacham (Insider), and Jatin Shah (EVP). Learn More on Karyopharm Therapeutics' active insiders.
Are insiders buying or selling shares of Karyopharm Therapeutics?: During the last twelve months, Karyopharm Therapeutics insiders bought shares 1 times. They purchased a total of 41,140 shares worth more than $50,190.80. During the last twelve months, insiders at the sold shares 23 times. They sold a total of 220,208 shares worth more than $298,322.89. The most recent insider tranaction occured on April, 4th when CEO Richard A Paulson sold 3,563 shares worth more than $4,596.27. Insiders at Karyopharm Therapeutics own 3.3% of the company. Learn More about insider trades at Karyopharm Therapeutics.
Information on this page was last updated on 4/4/2024.

Garen G. Bohlin Insider Trading History at Karyopharm Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/12/2023	Buy	41,140	$1.22	$50,190.80	45,140
5/6/2021	Buy	4,000	$7.82	$31,280.00	4,000

Garen G. Bohlin Buying and Selling Activity at Karyopharm Therapeutics

Karyopharm Therapeutics Company Overview

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Today's Range

Now: $1.25

$1.22

$1.31

50 Day Range

MA: $1.34

$1.10

$1.58

2 Week Range

Now: $1.25

$0.62

$4.11

Volume

621,960 shs

Average Volume

1,656,156 shs

Market Capitalization

$143.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.03

AI healthcare stock poised for 36,996% growth?

From Behind the Markets | Ad

Buy Alert Issued For AI Small Cap Our last two AI stocks jumped 150% and 130%... But we just issued a brand new "buy alert" for a new one...

Get the name of the stock here...